Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

Conditions:   Hepatocellular Carcinoma;   Liver Transplantation Intervention:   Drug: Camrelizumab treatment Sponsor:   Third Affiliated Hospital, Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials